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Abstract
Investing efficiently in future research to improve policy decisions is an important goal. Expected
Value of Sample Information (EVSI) can be used to select the specific design and sample size of
a proposed study by assessing the benefit of a range of different studies. Estimating EVSI with
the standard nested Monte Carlo algorithm has a notoriously high computational burden, especially
when using a complex decision model or when optimizing over study sample sizes and designs.
Therefore, a number of more efficient EVSI approximation methods have been developed. However,
these approximation methods have not been compared and therefore their relative advantages and
disadvantages are not clear.
A consortium of EVSI researchers, including the developers of several approximation methods,
compared four EVSI methods using three previously published health economic models. The ex-
amples were chosen to represent a range of real-world contexts, including situations with multiple
study outcomes, missing data, and data from an observational rather than a randomized study. The
computational speed and accuracy of each method were compared, and the relative advantages and
implementation challenges of the methods were highlighted.
In each example, the approximation methods took minutes or hours to achieve reasonably accurate
EVSI estimates, whereas the traditional Monte Carlo method took weeks. Specific methods are
particularly suited to problems where we wish to compare multiple proposed sample sizes, when the
proposed sample size is large, or when the health economic model is computationally expensive. All
the evaluated methods gave estimates similar to those given by traditional Monte Carlo, suggesting
that EVSI can now be efficiently computed with confidence in realistic examples.
Introduction
The Expected Value of Sample Information (EVSI) [1, 2] quantifies the expected benefit of undertak-
ing a potential future study that aims to reduce uncertainty about the parameters of a health economic
model. The expected net benefit of sampling (ENBS), which is the difference between EVSI and the
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expected research study costs, can be used to inform decisions regarding study design and research prior-
itization. The future study with the highest ENBS should be prioritized if we wish to maximize economic
efficiency. Thus, EVSI has the potential to determine the value of future research and to guide its design
when accounting for economic constraints.
Despite this potential, EVSI has rarely been used in practical settings for a variety of reasons [3]. In
the past, calculating EVSI in real-world scenarios has been based on nested Monte Carlo (MC) sampling
[4], and this is computationally costly if we wish to produce accurate estimates with high precision. This
computational burden is further increased when one aims to compute EVSI for multiple trial designs in
order to determine the optimal (i.e., with the highest ENBS) research study [5, 6]. High performance
computing resources can be used to overcome some of these barriers, but often at the expense of an
increased requirement for programming skills and an increase in the complexity of the analysis.
Several methods have been developed to overcome these computational barriers and unlock the po-
tential of EVSI as a tool for research prioritization and trial design optimization [7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17]. However, as many of these methods have been developed concurrently, they have not
been compared. Additionally, EVSI estimation methods are typically evaluated using health economic
models and trial designs chosen for computational convenience rather than those that reflect real-world
decision making.
Some of the EVSI estimation methods that have been proposed place restrictions on the structure
of the underlying health economic model and/or the study design [7, 8, 9]. These restrictions typically
take the form of an assumption about the study data that ensures that the prior and posterior model
parameter distributions take the same form (conjugacy), and by doing so, allow for computationally
efficient EVSI estimation. This, however restricts the applicability of these methods. EVSI estimation
based on minimal modelling, where a comprehensive clinical trial is available to inform EVSI estimation,
has also been proposed [18]. However, this paper aims to review EVSI estimation procedures for three
case studies where the health economic models are based on a diverse evidence base and, when combined
with the proposed study designs, do not fulfill the assumptions required for these restrictive or minimal
modelling methods.
Thus, our comparison is restricted to four recent calculation methods developed by (in chronological
order) Strong et al. [10], Menzies [11], Jalal and Alarid-Escudero [13] (extending a method proposed in
Jalal et al. [12]), and Heath et al. [15, 16, 17]. Whilst these methods are all based on different approaches
and assumptions, they all provide estimation techniques for approximating EVSI that, in comparison to
nested MC sampling methods, are less computationally demanding whilst retaining accuracy.
Our primary goal is to test the four EVSI estimation methods across a range of health economic
models and trial designs to gain a greater understanding of their behaviour in practice. We will evaluate
the accuracy of EVSI estimation methods across the three models and the computational time required
to obtain these estimates. These three models have several key features that reflect real-world trial design
and may make it challenging to estimate EVSI in practice. These are: the presence of multiple trial
outcomes, missingness or loss to follow-up in the data, and a study design that is observational rather
than randomized.
Notation and Key Concepts
Health economic decision making aims to determine the intervention, from some set of feasible al-
ternatives, that is expected to be optimal in terms of utility (which is usually net monetary benefit or
net health benefit [19]). We characterize a health economic model as a function that takes as an input a
vector of parameters θ, and returns the costs and health effects associated with each intervention in the
set of alternatives. Uncertainty in the input parameters is represented using a probability distribution
p(θ). To find the optimal intervention, costs and effects are combined into a single measure of economic
value by calculating the net benefit for each of the T treatment options considered relevant, conditional
on θ. Uncertainty about θ induces uncertainty about the net benefit for each treatment t = 1, . . . , T . We
denote the net benefit for treatment t given parameters θ as NBθt . Under the assumption of a rational,
risk neutral decision maker, the optimal intervention given current evidence is the intervention associated
with the maximum expected net benefit.
We consider that the model parameters can be split into two sets θ = (φ,ψ), where φ is a subset
of parameters that we wish to obtain more information on, and ψ are the remaining parameters. For
example, clinical trials are informative for clinical outcomes but may not collect information about
health state utilities or costs. The economic value of eliminating all uncertainty about φ (assuming risk
neutrality) is equal to the Expected Value of Partial Perfect Information (EVPPI) [20, 21, 22]. This is
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given by
EVPPI = Eφ
[
max
t
Eθ|φ
[
NBθt
]]
−max
t
Eθ
[
NBθt
]
. (1)
The EVSI is the value of collecting additional data, denoted X, to inform the parameters φ and is
bounded above by the EVPPI. If these data had been collected and observed to have a value x, they
would be combined with the current evidence to generate an updated distribution for φ, p(φ | x). Under
a Bayesian approach, this would in turn be used to update the distribution of the net benefit of each
treatment. The optimal intervention conditional on the data x is the treatment associated with the
maximum expected net benefit based on the updated knowledge about the relevant parameters φ. If
the optimal intervention changes, compared to the current decision, then the information in x has value.
However, as the data have not been collected yet (and may never be), the average value over all possible
datasets is considered. Mathematically, EVSI is defined as
EVSI = EX
[
max
t
Eθ|X
[
NBθt
]]
−max
t
Eθ
[
NBθt
]
, (2)
where the distribution ofX can be defined through p(X,θ) = p(θ)p(X | θ) where p(X | θ) = p(X | φ) is
the sampling distribution for the data given the parameters. We assume that the sampling distribution
for the data is only defined conditional on φ, i.e., does not provide information on the value of the
parameters ψ, except through any relationship with φ.
Calculation Methods for EVSI
It is rarely possible to compute EVSI analytically as the net benefit is often a complex function of θ.
Additionally, it is challenging to compute the expectation of a maximum analytically as required in the
first term of equation (2). Therefore, a range of methods have been developed to approximate EVSI.
Nested Monte Carlo Computations for EVSI
The simplest approximation method [4] computes all the expectations in equation (2) using MC
simulation. The second term can be computed by simulating s = 1, . . . , S parameter values, θs, from
p(θ). The simulated values are used as inputs to a health economic model to obtain S simulations
of the net benefit for each intervention, denoted NBθst . Note that this process is required to perform
a “probabilistic sensitivity analysis” (PSA) [23], used to assess the impact of parametric uncertainty
on the decision uncertainty, which is mandatory in various jurisdictions [24, 25, 26]. The average of
NBθ1t , . . . ,NB
θS
t for each intervention can be computed and maxt Eθ
[
NBθt
]
is estimated by the maximum
of these means.
The first term in equation (2) is more complex to compute by simulation. Firstly, S datasets Xs
must be generated conditional on the simulated θs from the assumed sampling distribution p(X | θs).
For each Xs, we simulate R values from the updated distribution of the model parameters p(θ | Xs).
These R simulations are used as inputs to the health economic model to simulate from the updated
distribution of the net benefit for each intervention. The mean net benefit for each treatment option is
then calculated to estimate Eθ|X
[
NBθt
]
for t = 1, . . . , T . The maximum of these simulated means is
then selected for each Xs. Thus, to compute EVSI by MC simulation, we require S × R runs of the
health economic model. This is computationally expensive for standard choices of S and R, which are
typically in the thousands. Therefore, the following methods focus on approximating the updated mean
of the incremental net benefit associated with each intervention t using a smaller simulation burden. We
denote the expectation of the incremental net benefit, conditional on data X, as
µXt = Eθ|X
[
NBθt
]
.
In a similar manner, we also denote the expectation of the incremental net benefit, conditional on some
value of the parameters of interest φ, as
µφt = Eθ|φ
[
NBθt
]
.
Finally, to increase the numerical stability of the following approximation methods, it is easier to work
in terms of the incremental net benefit or loss, defined, without loss of generality, as INBθt = NB
θ
t −NBθ1
for t = 2, . . . , T .
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Strong et al.
The Strong et al. method estimates EVSI by fitting a regression model between the simulated values
of the incremental net benefit, as the ‘dependent’ or ‘response’ variable, and a scalar or low-dimensional
summary for the simulated dataset X as the ‘independent’ or ‘predictor’ variable(s) [10]. This low-
dimensional summary for X should reflect how the data would be summarized if the study were to go
ahead and must be computed for each simulated dataset Xs. Once this regression model has been fitted,
µXt is estimated by the fitted values from this regression model. EVSI is then estimated directly from
these estimates of µXt .
Menzies
Menzies [11] presents two EVSI estimation methods, the most accurate of which estimates µXt by
reweighting simulations of µφt . This reweighting is based on the likelihood of observing a simulated
dataset X conditional on different values for φ. The term likelihood is used in the statistical sense and
is equal to p(X | φ).
This method simulates S future datasets Xs from p(X | φs). The likelihood for every simulated
vector for φ is then calculated conditional on Xs . For the sample Xs, µ
Xs
t is estimated as the average
of µφt , weighted by the likelihood of the dataset Xs, and the method can therefore be seen as an example
of importance sampling [27, 28]. EVSI is estimated based on the estimate of µXst for each future sample.
Jalal et al.
The Jalal et al. method published by Jalal and Alarid-Escudero [13], building on work from Jalal
et al. [12], fits a linear meta-model1 between the simulated incremental net benefit values, as the
response variable, and simulations for φ, as the predictor variables. Each term of the linear meta-model
is then rescaled based on a Gaussian-Gaussian Bayesian updating approach to estimate its “posterior”
expectation across different future datasets X. These estimated distributions are then recombined using
the coefficients of the linear model to estimate µXt and compute EVSI.
For a proposed future data collection strategy of size N , the rescaling factor for each term of the
linear meta-model is equal to
N
N +N0
,
where N0 is known as the prior effective sample size. In some prior-likelihood pairs, N0 can be obtained
analytically. In other settings, N0 can be estimated using one of two estimation methods. If the data
X can be summarized using a summary statistic W (X), then N0 can be computed as a function of
the variance of W (X). If a suitable statistic cannot be derived, then nested posterior sampling can be
used to estimate N0. In this method, S future datasets Xs, s = 1, . . . , S are simulated. Each of these
samples is used to update the information about the model parameters p(θ | Xs), typically using R
simulations and computing the mean for φ. The variance of the mean for φ, across different samples
Xs, is then used to estimate N0. Computationally, this nested sampling method to compute N0 is
relatively computationally expensive compared to the other two proposals to determine N0. However,
calculation of N0 is only needed once to compute EVSI across study size.
Heath et al.
The Heath et al. [16, 17] estimation method combines the simulations µφt and a modified nested MC
sampling method to estimate EVSI. This method reduces the number of times the updated distribution
of the net benefit must be simulated to estimate EVSI from S, typically at least 1000, to Q, usually
between 30 and 50 [17]. Thus, EVSI is estimated with Q×R health economic model runs.
The Heath et al. method uses nested MC sampling to estimate the variance of the incremental net
benefit for different future datasets. These estimated variances rescale simulations of µφt for t = 2, . . . , T
to approximate simulations of µXt which can be used to estimate EVSI. The Heath et al. method only
requires a single nested simulation procedure to estimate EVSI across sample size [17].
1A “linear” model is required for this method. However, non-linear functions of φ can be defined and combined linearly
to account for flexible relationships between the incremental net benefit and the parameters φ.
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Case Studies
These EVSI methods are applied to three case studies designed to explore trial designs using health
economic models that make EVSI estimation reflective of real-world decision making. The first case
study is a stylized chemotherapy example used to evaluate EVSI estimation in the presence of multiple
outcomes, reflecting a realistic trial design with a single primary, and multiple secondary, outcomes.
The second case study evaluates EVSI methods in the presence of missingness in the data using a
previously published health economic model to explore EVSI estimation when we account for standard
considerations in trial design and development. Finally, we evaluate EVSI methods for a health economic
model based on a time-dependent natural history model where the main data source is observational.
Case Study 1: A New Chemotherapy Treatment
This model was developed in Heath and Baio [16] to evaluate two chemotherapy interventions, i.e.,
the current standard of care and a novel treatment that reduces the number of adverse events. These
two options are equal in their clinical outcomes so we focus on the adverse events. The probability of
adverse events for the standard of care is denoted pi0 and ρ denotes the proportional reduction in the
probability of adverse events with the novel treatment.
All patients incur a treatment cost of £110 for the standard of care or £420 for the novel treatment.
Patients without adverse events or those that have recovered have a quality of life (QoL) measure of q.
The health economic impact of adverse events is modelled with a Markov model depicted in Figure 1. In
this model, γ1 and γ2 denote the constant probability of requiring hospital care and dying, respectively,
and λ1 and λ2 denote the constant probability of recovery given that an individual remains at home or
enter hospital, respectively. The cycle length is 1 day and the time horizon is 15 days. Recovered patients
incur no further cost while patients who die have a one-time cost of terminal care. There are costs and
QoL measures associated with home and hospital care. PSA distributions for the model parameters are
informed using previous data or defined using expert opinion with all distributional assumptions given
in the supplementary material.
Figure 1: A four state Markov model used to model the health economic impact of adverse events from
a chemotherapy treatment.
Sampling Distributions for X
The EVSI is computed for a future two-arm randomized control trial whose primary outcome is the
number of adverse events. As a secondary set of measures, the study monitors the treatment pathway
for patients who experience adverse events. Thus, the trial directly informs six model parameters φ =
(pi0, ρ, γ1, γ2, λ1, λ2) by collecting six outcomes. We will enrol 150 patients per arm.
To define the sampling distribution for the six outcomes, we model the number of adverse events
using binomial distributions conditional on pi0 and ρ;
XAE0 ∼ Bin(150, pi0) and XAE1 ∼ Bin(150, ρpi0).
The number of patients treated in hospital and the number of patients who die are modelled as
XHosp ∼ Bin(XAE0 +XAE1 , γ1) and XDeath ∼ Bin(XHosp, γ2).
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Finally, recovery time for patients who experience adverse events but recover is modelled with an expo-
nential distribution conditional on the transition probabilities λ1 and λ2,
T iHC ∼ Exponential(η1)
with η1 = − log(λ1) and i = 1, . . . , XAE0 + XAE1 − XHosp. The recovery time for every patient who
recovers in hospital is modelled as
T jH ∼ Exponential(η2)
with η2 = − log(λ2) and j = 1, . . . , XHosp −XDeath.
Case Study 2: A Model for Chronic Pain
This example uses a cost-effectiveness model developed by Sullivan et al. [29], and extended in Heath
et al. [17], to evaluate treatments for chronic pain. This is based on a Markov model with 10 states,
where each state has an associated QoL and cost. The model is initiated when a cohort of patients
receive their initial treatment for chronic pain. Patients can experience adverse events due to treatment
and can withdraw from treatment due to adverse events or lack of efficacy. Following this, they can be
offered an alternative therapy or withdraw from treatment. If they withdraw from this second line of
treatment, they can receive further treatment or discontinue, both considered absorbing states as the
model does not consider a death state.
As a treatment for chronic pain, a patient can first either be offered morphine or an innovative
treatment. If they withdraw, they are offered oxycodone as an alternative treatment. Thus, the only
difference between the two options is the first-line treatment where the innovative treatment is more
effective, more expensive and causes fewer adverse events. A more in-depth presentation of all the
model parameters is given in [29] where the parameter distributions are gamma for costs and beta for
probabilities and utilities. The means of these distributions are informed by relevant studies identified
following a literature review and the standard deviation is taken as 10% of the underlying mean estimate.
The per-person lifetime EVSI is calculated, assuming a discount factor of 0.03 per year over 15 years.
Sampling Distributions for X
EVSI is computed for a study that investigates the QoL weights for patients who remain on treatment
without any adverse events and of patients who withdraw from the first line of treatment due to lack
of efficacy. The individual level variability in these two QoL weights is modelled, for simplicity, as
independent beta distributions although the assumption of independence may be invalid [30]. The
population level mean QoL weight, i.e., the mean of the individual level QoL distribution, is defined
as the value of those two health states in the Markov Model. The standard deviations of the individual
level distributions is then set equal to 0.3, for patients who remain on treatment, and 0.31, for patients
who withdraw due to lack of efficacy [31]2. We compute EVSI for trials enrolling 10, 25, 50, 100 and 150
patients. We assume that only a proportion of the questionnaires are returned, leading to missingness
in the data.
To generate the data, a response rate of 68.7% is assumed, consistent with the return rate observed in
[32]. We generate a response indicator for each patient in the trial using a Bernoulli distribution. If this
indicator is 1, then we assume the patient returned the questionnaire and therefore we have observed
utility scores for both states for that patient, simulated from the beta distributions specified above,
conditional on the model parameters.
Case Study 3: A Model for Colorectal Cancer
This example uses a health economic model developed by Alarid-Escudero et al. [33] to evaluate
a screening strategy for colorectal cancer (CRC) and pre-cancerous lesions known as adenomas. This
model is based on a nine-state Markov model with age-dependent transition intensities which govern the
onset of adenomas (pre-cancerous growths) and the risk of all-cause mortality. The onset of adenomas
is modeled using a Weibull hazard conditional on age
l(a) = λ1ga
g−1
2This sampling distribution for the data causes some minor issues for the Gibbs sampling procedure used in the JAGS
program for Bayesian updating.
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where λ1 and g are the shape and scale parameters of the Weibull distribution and a is the age of the
patient. Model parameters are calibrated to observed literature and uncertainty in the model parameters
g and λ1 reflects the uncertainty in these calibration targets.
The costs and QoL associated with each health state are used to evaluate the economic burden of
CRC. The screening strategy is assumed to capture patients with adenomas and early cancer so they can
be operated on before the cancer progresses and becomes clinically detected. The proposed screening
strategy has a sensitivity with a mean of 0.98 and a specificity with a mean of 0.87. Some members of
the general population have undiagnosed adenomas and early stage CRC at the onset of the simulation.
Sampling Distributions for X
EVSI is computed for a study that investigates the onset of adenomas in the general population to
inform the shape and scale of the Weibull hazard function. A cross-section of the general population
aged between 25 and 90 without any screening history will be screened for the presence of adenomas
with a gold standard test with 100% sensitivity and specificity. Upon enrollment, the age of the subjects
is recorded to determine the age-specific risk. EVSI is computed for trials enrolling 5, 40, 100, 200, 500,
750, 1000 and 1500 participants.
To generate prospective data, we simulate the enrolment age for participants. Demographic data
from Canada in 2011, obtained from the Human Mortality Database [34], were used to generate study
subjects with an age distribution representative of the general population, with ages restricted between
25 and 90 years. Conditional on their age a, a participant has a probability
p(a) = 1− e−λ1ag
of having an adenoma or CRC. The outcome for a specific subject was simulated from a Bernoulli
distribution conditional on p(ai)
Xi ∼ Ber (p (ai))
where ai is the age of participant i. We assumed that there is no missing data as participants are enrolled
and undergo the test at the same clinic visit and no other data are collected.
Analysis
Comparing the presented EVSI estimation methods is challenging as their accuracy and computa-
tional time are dependent on choices made by the modeller and the computational efficiency of the
method implementation. Table 1 outlines the simulation choices that were made for the case studies.
These choices were made to achieve EVSI estimates with a reasonable level of precision, while keeping
the computation time manageable. For example, smaller sample sizes were necessary for models with
a greater computational cost. We compared the speed and accuracy achievable by each method, and
identified their relative advantages and challenges in practice.
The prior effective sample size for the Jalal et al. method needs to be computed once to estimate
the EVSI across sample size. As posterior updating is slower for larger sample sizes, it is preferable to
estimate N0 with a small proposed sample X. However, the estimation of N0 also relies on a Gaussian
approximation so the sample size of X should be sufficiently large to assume normality. Thus, the
table above (Jalal et al. future sample size) highlights the sample size of X used in the nested posterior
sampling to estimate N0 that balances accuracy and computational speed.
For the first two case studies, we computed a standard error for the EVSI estimates by recomputing
the EVSI 200 times, each time with the same PSA samples, so that this standard error reflects uncertainty
arising from any simulation involved in the EVSI estimation procedure itself.
To obtain the computational time for the four recent approximation methods, computations were
undertaken on a computer with an i7 Intel processor with 16 GB of RAM in R version 3.5.1. The
nested MC computations were undertaken on a Linux Google Compute Engine virtual machine. The
computation time give below is the total time across all cores. Code to undertake the computations in
this paper is available from GitHub at https://github.com/convoigroup/EVSI-in-practice.
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Simulation Choices
Case Study
Chemotherapy
side effects (1)
Chronic Pain
(2)
CRC screening
(3)
Initial PSA size 100,000 100,000 5,000
Number of µφt simulations
from EVPPI calculation
100,000 100,000 5,000
Nested simulation outer loop
size
100,000 100,000 NA
Nested simulation inner loop
size
100,000 100,000 NA
Strong et al. sample size 100,000 100,000 5,000
Menzies sample size 20,000 5,000 2,500
Jalal et al. N0 computation
method
nested posterior
sampling
nested posterior
sampling
nested posterior
sampling
Jalal et al. N0 estimation
outer loop size
1,000 1,000 5,000
Jalal et al. N0 estimation in-
ner loop size
10,000 10,000 5,000
Jalal et al. N0 estimation fu-
ture sample size
30 40 40
Heath et al. outer loop size 50 50 50
Heath et al. inner loop size 10,000 10,000 5,000
Table 1: The simulation choices to compute EVSI for the four recent approximation methods and the
nested MC method for case study 1, 2 and 3.
Results
Case Study 1: Chemotherapy Side Effects
Figure 2 displays the 95% central intervals for the four faster EVSI approximation methods, with
the nested MC estimate shown as a vertical line. All the methods produce EVSI estimates that are
relatively close to the EVSI estimated by nested MC sampling, which we assume is accurate given
the large simulation size. The 95% central interval for the Heath et al. method is the only interval
that contains the “true” value, represented by the nested MC EVSI. At the same time, the Heath et
al. estimate is associated with substantial variability compared to the other methods.
21 22 23 24
EVSI
MC
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Men
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Hea
Figure 2: The mean per-person EVSI estimates, across 200 simulated estimation procedures, for the
five methods under consideration for the chemotherapy example with a future sample size of 150 and
willingness-to-pay of £30, 000. The 95% central intervals from these 200 simulations are shown as
horizontal lines and the gold standard MC estimator is shown as a vertical line.
Implementing the Strong et al. and Jalal et al. methods involves finding a flexible regression model
that fits well and is computationally feasible to estimate. As there are six parameters in this example,
finding such a model was relatively challenging and required examination of residual plots.
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Case Study 2: Chronic Pain
Figure 3 shows that the 95% central intervals for the Heath et al. and the Menzies methods contain
the nested MC estimate, which we assume to be accurate given the large simulation size, for all sample
sizes. However, all methods are relatively close to the nested MC estimate. The Strong et al. method
produced the shortest 95% central intervals while the three alternatives are relatively comparable. Note
that the Menzies estimate is based on a smaller PSA simulation size but still offers similar variability
compared to the other methods.
400 500 600 700 800 900
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N
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N
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= 
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0
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0
EVPPI
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Figure 3: The mean EVSI estimates, across 200 simulated estimation procedures, for the five methods
under consideration for the chronic pain example. EVSI was calculated across 5 different sample sizes
for the future trial. The 95% central intervals from these 200 simulations are shown as horizontal lines
and the gold standard MC estimator is shown as a vertical line.
In this example, the summary statistic used for the Strong et al. method is the geometric mean of X
and 1−X. These statistics are sufficient to estimate the model parameters of the beta distribution and
were derived using the Fisher-Neymann factorization theorem [35]. Summarizing X using the arithmetic
mean and variance gives incorrect EVSI estimates for this case study.
Case Study 3: Colorectal Cancer
Figure 4 demonstrates a broad consensus among the four recent approximation methods for the CRC
screening model. Nested MC simulations are not undertaken for this case study due to the computational
time required to obtain suitably accurate estimates for comparison. Thus, while we can note that the
four methods give similar results, we cannot assert that these EVSI estimates are “correct.”
For a sample size of 1,500, the Menzies EVSI estimate is incorrect. This is because the likelihood
tends to 0 for large sample sizes making the weighted samples difficult to approximate. Furthermore,
the Menzies method slightly over-estimates the EVSI for sample sizes between 500 and 1000. This is
9
because we only use a subset of the PSA simulations to obtain this EVSI estimate and the EVPPI, upper
limit for EVSI, estimated using this subset is slightly over-estimated, judging from the full 5,000 PSA
simulations.
50
0
10
00
15
00
Sample Size (Log−scale)
EV
SI
5 40 100 200 500 750 1000 1500
Heath
Jalal
Menzies
Strong
EVPPI
Figure 4: EVSI estimates for the four methods under consideration for the CRC model. EVSI is calcu-
lated for 9 different sample sizes for the future trial and is plotted across sample size. The sample size is
plotted on the log scale with the sample sizes marked on the natural scale. The EVPPI, computed using
the Strong et al. EVPPI computation method [36], is included as a black line on this Figure.
Computational Time
Table 2 shows the computational time for the five EVSI computation methods for each of the three
case studies. For the first two case studies, all four alternatives are considerably faster than the nested
MC method. For the third case study, the computational cost of the underlying CRC model meant that
it was not computationally feasible to use the nested Monte Carlo method.
For the first two case studies, the Heath et al. method has the lowest computation time as the under-
lying health economic model is fast. The Heath et al. method also estimates EVSI across multiple sample
sizes simultaneously which improves the computational time for the Chronic Pain example compared to
the Strong et al., and Menzies methods. For these two examples, the computation time required to
fit an accurate regression model is relatively high, increasing the computation time for the Strong et
al. method. The Jalal et al. method has the highest computation time as it uses nested MC simulation
to calculate N0. However, after estimating N0, EVSI can be re-estimated for any sample size. Thus, if
EVSI was to be estimated across more sample sizes, the Jalal et al. method would offer computational
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savings on the Strong et al., and Menzies methods. For the Chemotherapy example, the Menzies method
has a similar computational cost to the other three methods. However, it is estimated based on a reduced
simulation size; if all 100,000 PSA simulations are used, the computation time is greater than 2 hours.
For the Chronic Pain example, the Menzies method is noticeably slower as the computation time for the
likelihood increases when the proposed sample size of X is larger.
Case Study
Computational Time (mins)
Nested MC Strong et al. Menzies Jalal et al. Heath et al.
1: Chemotherapy 60480 6.45 4.45 7.47 1.48
2: Chronic Pain 223200 12.05 86 22.27 2.46
3: Colorectal Cancer ∗ 27.24 91 7.17 492
Table 2: The computational time required to produce EVSI estimates for the five methods under con-
sideration for the three case studies presented in this review.
For the CRC screening example, the Jalal et al. method is fastest because, even thoughN0 is estimated
through nested MC simulation, it must only be computed once to estimate the EVSI across sample size.
In contrast, for the Strong et al., method, X is summarized by finding the maximum likelihood estimates
(MLE) for g and λ1 that must be estimated, using relatively slow computational optimization procedures,
for each sample Xs, s = 1, . . . , S and sample size. Thus, estimating the summary statistics is slow in this
case study. The Heath et al. method is more computationally expensive as the underlying probabilistic
sensitivity analysis for the CRC health economic model is expensive and must be rerun Q×S = 250, 000
times to compute EVSI. The computational time of the Menzies method is similar to the previous case
studies.
Discussion
The paper uses three case studies to assess four novel methods for approximating EVSI. These meth-
ods were developed in response to the immense computational burden required to estimate EVSI using
nested MC simulations. As these methods were developed concurrently, no head-to-head comparison
has been undertaken. Additionally, these methods have typically been assessed using health economic
models designed for computational simplicity rather than reflecting real-life decision making.
Thus, we compared these four methods using case studies designed to cover a number of different
trial designs, interventions and health economic model structures that may make the EVSI estimation
more challenging. In general, the EVSI estimates were accurate when the underlying assumptions for
the respective methods were met, highlighting the importance of checking these assumptions. The
computational complexity of these methods varies for different health economic models, different sampling
distributions for the future data, and depending on whether optimization over different sample sizes is
required.
In general, we find that the four methods are comparable in terms of accuracy and computational
time in these more realistic situations. However, it should be noted that appropriately assessing accu-
racy is challenging because differences in the EVSI estimate could lead to alternative future research
recommendations, even when the difference is small. This is especially true for diseases with high inci-
dence as the EVSI is multiplied by the incidence to determine whether the trial offers value for research
investment. The determination of whether the EVSI is sufficiently precise will depend on the decision
problem at hand, so care should be taken when interpreting these results.
It is likely to be more useful to compare these methods on their ease of implementation. The “optimal”
estimation method trading off accuracy, precision, computational time and ease of implementation will
change depending on the health economic model structure, proposed trial design and analyst expertise.
Due to the differences between these four methods and the inherent differences in health economic models
and trial designs, giving general purpose recommendations is not simple and would not be unconditional.
Nonetheless, this analysis highlights that the Strong et al. is accurate and efficient, provided the
analyst can correctly summarize the trial data and fit a regression model. The Menzies method is
accurate but computationally relatively expensive for large PSA simulation sizes. The Jalal et al. method
is efficient when estimating EVSI across sample size but may require nested posterior sampling when
considering realistic data collection exercises. Finally, the Heath et al. method is accurate and efficient
when the health economic model has a low computation time but becomes more unfeasible as the model
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becomes more expensive. The Jalal et al. and Heath et al. methods required expertise in Bayesian
methods for all the examples in this paper.
While further research is required to give comprehensive guidance on the situations in which each of
these methods is most useful, we can conclude that, provided the underlying assumptions of the method
are met, any of the four methods chosen is likely to produce reasonable estimates in reasonable amount
of time.
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A Inputs for the Chemotherapy Model
Model Input Distribution 1st Prior Parameter 2nd Prior Parameter Previous Data
pi0 - Probability of adverse events Beta 1 1 Number of adverse events
ρ - Reduction in adverse events with
treatment
Normal Mean: 0.65 Precision: 100 No
q - QoL weight with no adverse events Beta 18.23 0.372 No
Γ1 - Probability of hospitalization Beta 1 1 Number of hospitalizations
Γ2 - Probability of death Beta 1 1 Number of deaths
γ1 - Daily transition probability to hos-
pital
Γ1
15 - - -
γ2 - Daily probability of death
Γ2
15 - - -
λ1 - Daily probability of recovery from
home care
Beta 5.12 6.26 No
λ2 - Daily probability of recovery from
hospital
Beta 3.63 6.74 No
Cost of death LogNormal 8.33 0.13 No
Cost of home care LogNormal 7.74 0.039 No
Cost of hospitalization LogNormal 8.77 0.15 No
QoL weight for home care Beta 5.75 5.75 No
QoL weight for hospitalization Beta 0.87 3.47 No
Table 3: The prior specification for the parameters underlying the Chemotherapy example including the
distributional assumption and its parameters. Unless specified, the parameters are specified in the order
used in the JAGS language for Bayesian updating. We indicate whether the stated prior is combined
with data in the probabilistic health economic model.
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